Naba Alsaha posts 8% growth in H1 2022 net profit to SAR 15.4 mln

15/09/2022 Argaam Exclusive
3

Naba Alsaha Medical Services Co. posted a rise of 8% in H1 2022 net profit after Zakat and tax to SAR 15.4 million, compared to SAR 14.2 million in the year-earlier period.

The profit growth was spurred by eased COVID-19 restrictions, which led to a significant improvement in outpatient revenues. Accordingly, it had a positive impact on improving the bed occupancy rate in the suites, which stood at 97% during the first half of 2022 compared to 86% in H1 2021.

 

Shareholders equity, after minority interest, reached SAR 118.25 million as of June 30, 2022, up from SAR 102.86 million a year earlier.



Current Half Annual Comparison (M)

Compared With The
Item H1 2021 H1 2022 Change‬
Revenues 56.56 62.90 11.2 %
Gross Income 23.16 27.34 18.1 %
Operating Income 14.17 15.65 10.4 %
Net Income 14.23 15.39 8.2 %
Average Shares 10.50 10.50 -
Earnings Per Share before unusual items 1.36 1.47 8.2 %
EPS (Riyals) 1.36 1.47 8.2 %

Naba Alsaha restated its 2021 financial statements to accommodate the first time adoption of “IFRS 16 – Leases”. Required adjustments and disclosure were made in that financial statements in accordance with “IAS 8 - Accounting policies, change in accounting estimates and errors”.

 

Accordingly, required adjustments were also made to the comparative figures in these condensed interim financial statements for the six months period ended June 30, 2022.

View more financial results

 

View other reports

Share Price

Naba Alsaha Medical Services Co.
69.90
(0.50) (0.71 %)

Naba Alsaha Medical Services Co. (NABA ALSAHA)

1 Day (0.71 %) 5 Days (9.81 %) 3 Months (10.84 %) 6 Months (14.76 %) Year (14.23 %) 2 Years 92.14 % 5 Years 99.44 % All 99.44 %
Created with Highstock 6.0.710:5511:0011:0511:3011:5012:1512:2512:4012:4512:5012:5513:0513:3013:4013:5014:0514:1014:1514:4514:5069.469.669.87070.270.470.670.8
Close : 69.80 | Apr 10, 14:53
More


Financial Ratios
Current
Market Cap (M Riyal) 733.95
Enterprise Value (EV) (M) 776.13
Shares Outstanding ((M)) 10.50
Book Value (BV) ( Riyal) 19.02
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) 33.64
Price/book 3.68
more


Financial results (Million)

Period Revenues Change Gross Income Change Operating Income Change
H1 2013 - - - - - -
H2 2013 - - - - - -
H1 2014 - - - - - -
H2 2014 - - - - - -
H1 2015 - - - - - -
H2 2015 - - - - - -
H1 2016 - - - - - -
H2 2016 - - - - - -
H1 2017 - - - - - -
H2 2017 - - - - - -
H1 2018 - - - - - -
H2 2018 - - - - - -
H1 2019 - - - - - -
H2 2019 - - - - - -
H1 2020 - - - - - -
H2 2020 - - - - - -
H1 2021 56.56 - 23.16 - 14.17 -
H2 2021 61.12 - 23.63 - 12.80 -
2021 117.68 1.7 % 46.78 1.9 % 26.97 (2.4 %)
H1 2022 62.90 11.2 % 27.34 18.1 % 15.65 10.4 %


Profit Performance (Million)

Period Net Income Change EPS(Riyal) Extraordinary Income/Expense Net Profit Before Unusual Items Earnings Per Share before unusual items
H1 2013 - - - - - -
H2 2013 - - - - - -
H1 2014 - - - - - -
H2 2014 - - - - - -
H1 2015 - - - - - -
H2 2015 - - - - - -
H1 2016 - - - - - -
H2 2016 - - - - - -
H1 2017 - - - - - -
H2 2017 - - - - - -
H1 2018 - - - - - -
H2 2018 - - - - - -
H1 2019 - - - - - -
H2 2019 - - - - - -
H1 2020 - - - - - -
H2 2020 - - - - - -
H1 2021 14.23 - 1.36 - 14.23 1.36
H2 2021 11.60 - 1.10 - 11.60 1.10
2021 25.83 (3.1 %) 2.46 - 25.83 2.46
H1 2022 15.39 8.2 % 1.47 - 15.39 1.47

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
H1 2013 - - -
H2 2013 - - -
H1 2014 - - -
H2 2014 - - -
H1 2015 - - -
H2 2015 - - -
H1 2016 - - -
H2 2016 - - -
H1 2017 - - -
H2 2017 - - -
H1 2018 - - -
H2 2018 - - -
H1 2019 - - -
H2 2019 - - -
H1 2020 - - -
H2 2020 - - -
H1 2021 - - -
H2 2021 39.75 % 28.12 % 21.95 %
H1 2022 41.09 % 27.54 % 21.76 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Earnings Per Share before unusual items (Riyal) Book Value (BV)
H1 2013 - - - -
H2 2013 - - - -
H1 2014 - - - -
H2 2014 - - - -
H1 2015 - - - -
H2 2015 - - - -
H1 2016 - - - -
H2 2016 - - - -
H1 2017 - - - -
H2 2017 - - - -
H1 2018 - - - -
H2 2018 - - - -
H1 2019 - - - -
H2 2019 - - - -
H1 2020 - - - -
H2 2020 - - - -
H1 2021 10.50 - - 8.82
H2 2021 10.50 2.46 2.46 9.80
H1 2022 10.50 2.57 2.57 11.26

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
H1 2013 - - -
H2 2013 - - -
H1 2014 - - -
H2 2014 - - -
H1 2015 - - -
H2 2015 - - -
H1 2016 - - -
H2 2016 - - -
H1 2017 - - -
H2 2017 - - -
H1 2018 - - -
H2 2018 - - -
H1 2019 - - -
H2 2019 - - -
H1 2020 - - -
H2 2020 - - -
H1 2021 - - -
H2 2021 - - -
H1 2022 - - -

Business Segments (Million)

Compared With The
Period Medical Services Pharmaceuticals
Q2 2022 57.77 5.13

Comments 3

1
18
3847

ابو ريم 11

منذ 1 سنه

حرفيا لقالك نتائج من خلف التريلات الى متى استخفاع عقولنا ؟؟

المصيبه تبريراتهم اقبح من نتائجهم مافي جديد العب ياله .....!

2
0
173

اول خطوة

منذ 1 سنه

الايرادات مرتفعة ماشاء الله ممتاز 

توسع الشركة في اعمالها والدخول في قطاعات اخرى ونتج عن ذلك الحصول على مشاريع جديدة ممتاز

3
2
74

محمد سليمان النادر

منذ 1 سنه

ايش تنفعني الايرادات ارتفعت...

اهم شي الربحية مجدية

انخفاض الارباح  81% قويه

يعني الاعلان مثل القادم ملان خسارة 

ولنا عبره في ملان

 

loader Train
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Popular Links

Quick Links

Join Us

Argaam.com Copyright © 2025, Argaam Investment, All Rights Reserved
Call Request

Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.

Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website